AMRX Stock Overview
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.
Amneal Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.34|
|52 Week High||US$5.13|
|52 Week Low||US$1.95|
|1 Month Change||0.43%|
|3 Month Change||1.30%|
|1 Year Change||-42.79%|
|3 Year Change||-53.57%|
|5 Year Change||n/a|
|Change since IPO||-84.41%|
Recent News & Updates
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance SheetSep 01
Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of DebtApr 16
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance SheetNov 23
Is Amneal Pharmaceuticals (NYSE:AMRX) A Risky Investment?Apr 28
What Percentage Of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Shares Do Insiders Own?Feb 28
A Closer Look At Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) Uninspiring ROEFeb 05
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt ExtensivelyJan 10
Are Amneal Pharmaceuticals's (NYSE:AMRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?Dec 06
|AMRX||US Pharmaceuticals||US Market|
Return vs Industry: AMRX underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.
Return vs Market: AMRX underperformed the US Market which returned -21.2% over the past year.
|AMRX Average Weekly Movement||8.7%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: AMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AMRX's weekly volatility (9%) has been stable over the past year.
About the Company
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Amneal Pharmaceuticals, Inc. Fundamentals Summary
|AMRX fundamental statistics|
Is AMRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMRX income statement (TTM)|
|Cost of Revenue||US$1.38b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.87|
|Net Profit Margin||-6.17%|
How did AMRX perform over the long term?See historical performance and comparison